[Cognitive impairment and tactics of using the drug Cerebrolysin. Resolution of the International Council of Experts (May 12, 2023)]. / Kognitivnye narusheniya i taktika primeneniya preparata Tserebrolizin. Rezolyutsiya mezhdunarodnogo soveta ekspertov (12 maya 2023 g.).

The aging of the population and the associated increase in the share of cognitive impairments in the structure of a wide range of diseases are a serious challenge for modern healthcare. Difficulties in the treatment of cognitive disorders are determined by many factors, including the age of patients, comorbidity, forced polypragmasia and the adequacy of the dosage of drugs that restore cognitive activity. The experts discussed information about the therapeutic potential of the drug Cerebrolysin in the treatment of cognitive disorders of various origins, stated significant experience of its effective and safe use in many clinical studies in mild and moderate forms of dementia. At the same time, there was a lack of consistent and systematic data on the dosage regimen, frequency, and duration of use of the drug in different forms of cognitive impairment and the degree of their severity. The aim of the international council of experts was to determine the optimal dosage regimens of the drug Cerebrolysin in patients with various etiologies and severity of cognitive impairment. The result of the work was the approval of a unified scheme for the use of the drug Cerebrolysin, considering the severity of the disease and its duration.

[Optimization of secondary prevention in patients with high-risk atherothrombotic ischemic stroke or transient ischemic attacks]. / Optimizatsiya vtorichnoi profilaktiki serdechno-sosudistykh sobytii u patsientov s aterotromboticheskim ishemicheskim insul'tom ili tranzitornymi ishemicheskimi atakami vysokogo riska.

High and very high risk atherothrombotic ischemic stroke (ATIS) includes patients with severe extracranial atherosclerosis, any intracranial atherosclerosis, and aortic arch atheromatosis. The article discusses the most effective approaches to medical short- and long-term secondary prevention of ATIS, major vascular events and death, based on the results of modern research and current clinical guidelines. Clinical studies of recent years have proven the possibility of individualization and intensification of secondary prevention of ATIS. In the treatment of high-risk patients, it is advisable to use more widely short-term dual antiplatelet therapy (combination of ASA with clopidogrel or ticagrelor), long-term dual antithrombotic therapy (combination of ASA and rivaroxaban at a dose of 2.5 mg twice a day not earlier than 30 days from the development of stroke or TIA) to reduce the risk of recurrent stroke and death, as well as intensive lipid-lowering therapy (including the use of a combination of statins and ezetimibe or PCSK9 inhibitors).

[Current approaches in the treatment and rehabilitation of patients with neurological diseases after COVID-19. Resolution of the International Experts Forum]. / Lechenie i reabilitatsiya bol'nykh s nevrologicheskimi narusheniyami posle perenesennogo COVID-19. Rezolyutsiya Mezhdunarodnogo foruma ekspertov.

Despite the significant shift in global attention away from the pandemic, the problem of a new coronavirus infection remains important in the medical community. Almost 3 years after the start of the COVID-19 pandemic the issues of rehabilitation and management of delayed manifestations and sequelae of the disease are especially important. According to numerous available data, the new coronavirus infection is characterized by multiorgan lesions. Respiratory dysfunction, clotting disorders, myocardial dysfunction and various arrhythmias, acute coronary syndrome, acute renal failure, GI disorders, hepatocellular damage, hyperglycemia and ketosis, dermatological complications, ophthalmological symptoms and neurological disorders may be found. Significant prevalence of the latter in the post-coronavirus period necessitated this International Expert Forum to develop unified approaches to the management of patients with neurological complications and sequelae of new coronavirus infection based on practical experience and considering the scientific information available on COVID-19. The expert council developed a resolution formulating the tactics for the management of patients with neurological manifestations of COVID-19.

[A progressive view on the treatment and rehabilitation of acute ischemic stroke]. / Progressivnyi vzglyad na lechenie i reabilitatsiyu ostrogo ishemicheskogo insul'ta.

The review discusses the data on efficacy and safety of reperfusion therapy and neuroprotective therapy in ischemic stroke (IS) and during the rehabilitation. The authors recommend using an individual approach to the treatment of patients with acute IS and identify patients in whom neurotrophic therapy will bring the greatest effect. In addition, it is concluded that pharmacological support is an integral part of the rehabilitation of patients after a stroke, along with the correct assessment of neurological deficits, the timely start of rehabilitation measures, the complexity and continuity at all stages.

[Topical issues of adequate control of dyslipidemia in the prevention of acute and recurrent cerebral circulatory disorders of ischemic type]. / Aktual'nye voprosy adekvatnogo kontrolya dislipidemii v profilaktike ostrykh i povtornykh narushenii mozgovogo krovoobrashcheniya po ishemicheskomu tipu.

Ischemic stroke (IS) is one of the main causes of death and permanent disability. Reducing the burden of stroke is possible if effective preventive measures are provided. The possibilities of correcting lipid metabolism as an important measure aimed at preventing IS are analyzed.

[The efficacy of prevention of postoperative cognitive dysfunction in cardiac surgeries with the use of the cerebrolysin]. / Éffektivnost' profilaktiki posleoperatsionnoi kognitivnoi disfunktsii pri kardiokhirurgicheskikh vmeshatel'stvakh s primeneniem tserebrolizina.

AIM: To assess the efficacy of postoperative cytoprotection with cerebrolysin in cardiac surgeries without using cardiopulmonary bypass and to analyze the changes in the blood circulation in the postoperative period in groups with- and without cerebrolysin preconditioning. MATERIAL AND METHODS: Thirty-eight patients, who underwent coronary and mammaro-coronary bypass grafting without using cardiopulmonary bypass, were included in the study. Fifteen patients received cerebrolysin before surgery. RESULTS AND CONCLUSION: Cerebrolysin improved cognitive test scores. Positive changes on anxiety and depression scales were observed as well. In the group of patients treated with cerebrolysin, quantitative parameters of the cerebral blood flow were in stable condition, with a slight increase on the 10th day after surgery, which may indicate increasing stress resistance of cells of the central nervous system after appropriate pharmacological protection.